BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 10998548)

  • 1. The nociceptin/orphanin FQ receptor ligand acetyl-RYYRIK-amide exhibits antagonistic and agonistic properties.
    Berger H; Bigoni R; Albrecht E; Richter RM; Krause E; Bienert M; Calo' G
    Peptides; 2000 Jul; 21(7):1131-9. PubMed ID: 10998548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nphe(1)]NC(1-13)NH(2) selectively antagonizes nociceptin/orphanin FQ-stimulated G-protein activation in rat brain.
    Berger H; Calo' G; Albrecht E; Guerrini R; Bienert M
    J Pharmacol Exp Ther; 2000 Aug; 294(2):428-33. PubMed ID: 10900215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ.
    Berger H; Albrecht E; Wallukat G; Bienert M
    Br J Pharmacol; 1999 Feb; 126(3):555-8. PubMed ID: 10188961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterization of Ac-RYYRWK-NH(2), Ac-RYYRIK-NH(2) and [Phe1Psi(CH(2)-NH)Gly2] nociceptin(1-13)NH(2) at rat native and recombinant ORL(1) receptors.
    Mason SL; Ho M; Nicholson J; McKnight AT
    Neuropeptides; 2001; 35(5-6):244-56. PubMed ID: 12030809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.
    Bojnik E; Babos F; Fischetti C; Magyar A; Camarda V; Borsodi A; Bajusz S; Calo' G; Benyhe S
    Brain Res Bull; 2010 Mar; 81(4-5):477-83. PubMed ID: 19800951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
    Gündüz O; Rizzi A; Baldisserotto A; Guerrini R; Spagnolo B; Gavioli EC; Kocsis L; Magyar A; Benyhe S; Borsodi A; Calò G
    Eur J Pharmacol; 2006 Jun; 539(1-2):39-48. PubMed ID: 16682024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of GTPgamma[35S] is regulated by GDP and receptor activation. Studies with the nociceptin/orphanin FQ receptor.
    McDonald J; Lambert DG
    Br J Pharmacol; 2010 Mar; 159(6):1286-93. PubMed ID: 20148892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol.
    Bojnik E; Farkas J; Magyar A; Tömböly C; Güçlü U; Gündüz O; Borsodi A; Corbani M; Benyhe S
    Neurochem Int; 2009 Dec; 55(7):458-66. PubMed ID: 19414055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro binding and functional studies of Ac-RYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin F/Q receptor.
    Gunduz O; Sipos F; Spagnolo B; Kocsis L; Magyar A; Orosz G; Borsodi A; Calò G; Benyhe S
    Neurosignals; 2006-2007; 15(2):91-101. PubMed ID: 16874009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells.
    Wright KE; McDonald J; Barnes TA; Rowbotham DJ; Guerrini R; Calo' G; Lambert DG
    Neurosci Lett; 2003 Aug; 346(3):145-8. PubMed ID: 12853105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological investigation of novel nociceptin/OFQ analogues and N/OFQ-RYYRIK hybrid peptides.
    Erdei AI; Borbély A; Magyar A; Szűcs E; Ötvös F; Gombos D; Al-Khrasani M; Stefanucci A; Dimmito MP; Luisi G; Mollica A; Benyhe S
    Peptides; 2019 Feb; 112():106-113. PubMed ID: 30513351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.
    Kitayama M; Barnes TA; Carra G; McDonald J; Calo G; Guerrini R; Rowbotham DJ; Smith G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):528-37. PubMed ID: 14598020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes.
    Johnson EE; McDonald J; Nicol B; Guerrini R; Lambert DG
    Brain Res; 2004 Apr; 1003(1-2):18-25. PubMed ID: 15019559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Species differences in the efficacy of compounds at the nociceptin receptor (ORL1).
    Burnside JL; Rodriguez L; Toll L
    Peptides; 2000 Jul; 21(7):1147-54. PubMed ID: 10998550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
    McDonald J; Barnes TA; Calo G; Guerrini R; Rowbotham DJ; Lambert DG
    Eur J Pharmacol; 2002 May; 443(1-3):7-12. PubMed ID: 12044785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPgamma(35)S binding studies.
    McDonald J; Calo G; Guerrini R; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Feb; 367(2):183-7. PubMed ID: 12595960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function.
    Kapusta DR; Burmeister MA; Calo' G; Guerrini R; Gottlieb HB; Kenigs VA
    J Pharmacol Exp Ther; 2005 Aug; 314(2):643-51. PubMed ID: 15855356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
    Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
    J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.
    Ibba M; Kitayama M; McDonald J; Calo G; Guerrini R; Farkas J; Toth G; Lambert DG
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):553-61. PubMed ID: 18807245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.
    Kapusta DR; Thorkildsen C; Kenigs VA; Meier E; Vinge MM; Quist C; Petersen JS
    J Pharmacol Exp Ther; 2005 Aug; 314(2):652-60. PubMed ID: 15855355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.